Understanding GLP-1 Medications and Vision: What the IRD Community Needs to Know

For individuals and families navigating inherited retinal diseases (IRDs), any news concerning vision health is of paramount importance. Recent discussions have emerged regarding glucagon-like peptide-1 (GLP-1) medications, commonly used for Type 2 diabetes and weight management, and their potential link to certain eye conditions. While the overall risk to vision is considered low, understanding these findings is crucial for our community, especially as these medications become more widespread. This article aims to clarify the current understanding based on recent research, helping patients and their families make informed decisions with their healthcare providers.

Key Findings on GLP-1s and Vision

Recent studies have explored the relationship between GLP-1 medications, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), and various eye conditions. One significant area of focus has been non-arteritic anterior ischemic optic neuropathy (NAION), a condition involving reduced blood flow to the optic nerve that can cause sudden vision loss.

  • Small, but Present Risk: Rutgers researchers found an association between GLP-1 use and a higher risk for ischemic optic neuropathy, though the overall risk remained low. Specifically, the increase in risk was estimated to be small, approximately three to four additional cases per 10,000 patients treated with GLP-1s over 18 months. This condition can be clinically important because it may involve sudden vision loss.
  • Conflicting Information on Other Conditions: Research presents conflicting findings regarding GLP-1s and other eye conditions like diabetic retinopathy and age-related macular degeneration (AMD). While some initial studies indicated that diabetic retinopathy could worsen, more recent large-scale data suggests no increased risk. Similarly, studies on AMD have shown conflicting results. One study reported that older adults with diabetes taking GLP-1 medications might have a heightened risk for neovascular age-related macular degeneration (nAMD), with a relative doubling of risk, though the absolute risk remained low. However, another study following over 200,000 adult GLP-1 users found no statistical link between these drugs and the risk of developing neovascular age-related macular degeneration.
  • Regulatory Warnings: Australia's Therapeutic Goods Administration (TGA) has updated product information for several GLP-1 RA medicines to include a warning about the potential for NAION, urging patients to seek urgent medical attention for sudden vision loss. The TGA emphasized that NAION is a rare but severe eye disorder that may result in permanent visual impairment.

What This Means for Patients and Families

For most individuals using GLP-1 agonists, the benefits for managing Type 2 diabetes, obesity, and reducing cardiovascular and kidney disease risks are considered to outweigh these rare eye-related risks. However, awareness is key. Patients currently taking or considering GLP-1 medications should discuss these potential risks with their healthcare providers, especially if they have pre-existing eye conditions or are at higher baseline risk for NAION.

It is crucial to watch for any sudden or unexplained changes in vision, including painless vision loss, blurring in one eye, dimming of vision, changes in color perception, or missing areas in the field of view. Any such symptoms should be reported to a doctor immediately.

Looking Ahead

The medical community continues to research the long-term effects of GLP-1 medications. As their use grows, ongoing studies will provide more clarity on potential side effects and their implications for eye health. Staying informed and maintaining open communication with healthcare teams remains the best approach for managing overall health, including vision, within the IRD community.